Johnson & Johnson’s MedTech segment delivered 5.4% operational sales growth in 2025, reaching $33.8 billion globally, slightly outpacing the 5.3% growth in its Innovative Medicine segment, which totaled $60.4 billion. The MedTech outperformance was driven by strong demand for electrophysiology devices and Abiomed technologies in the Cardiovascular business, as well as wound closure systems in General Surgery. In the Innovative Medicine portfolio, leading oncology treatments such as Darzalex and Carvykti, along with immunology assets Tremfya and Simponi, underpinned performance despite headwinds from biosimilar competition to Stelara.

Over the past year, Johnson & Johnson introduced 15 major new products and secured more than 40 regulatory approvals across key markets, supported by over 60 ongoing clinical trials. The acquisition of Shockwave Medical in May 2024 bolstered the MedTech pipeline, with Shockwave’s intravascular lithotripsy platform achieving 23% operational growth in the fourth quarter and Abiomed delivering 18% growth. During 2025, both Shockwave and Carvykti surpassed $1 billion in annual sales, bringing to 28 the number of Johnson & Johnson platforms generating at least that threshold in revenue.

Looking ahead, Johnson & Johnson forecasts worldwide operational sales growth of 5.7% to 6.2% for full-year 2026, implying total sales between $99.5 billion and $100.5 billion. The company projects adjusted earnings per share in the range of $11.43 to $11.63, reflecting continued diversification across its MedTech and biopharma divisions. CEO Joaquin Duato highlighted the company’s breadth of growth drivers and stated that Johnson & Johnson will soon stand alone as the only healthcare firm to exceed $100 billion in annual revenues.